High-dose interleukin-2 (hd-IL2) in treatment-naïve metastatic renal cell carcinoma (mrcc) - a 10 year single-site experience and outcome of prospective pathology-based patient selection. (6th November 2014) - Chow, Shien; Evans, Manon; Galvis, Victoria; Leach, Rebecca; Keene, Elizabeth; Chan, Kevin; Spencer-Shaw, Andrea; Jonathan, Shanks; Shabalak, Alaaeldin; Thistlethwaite, Fiona; Hawkins, Robert